Inhaled HRS-9821 Safety Study in Healthy People and COPD Patients
Part of Lungs & breathing clinical trials.
This is an early-stage study testing a new inhaled medication (HRS-9821) to see if it is safe and how the body processes it. Researchers will first test it in healthy volunteers, then in people with COPD (chronic lung disease) to understand if it might help with breathing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are willing and able to give informed consent and follow all study procedures
- Your body weight is at least 45 kg and your BMI (weight-to-height ratio) is between 18–33
- Your heart rhythm (ECG) is normal or has only minor, non-concerning abnormalities
- You agree to use contraception (birth control) for 1–3 months after the last dose
- You can use the study inhaler device correctly as instructed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new inhaled medication, HRS-9821, in healthy people and in people with COPD. For COPD patients, the goal is to see how safe and well-tolerated multiple doses are, which could lead to a new treatment option.
This trial tests whether an inhaled medication called HRS-9821 can help people with moderate to severe COPD (chronic obstructive pulmonary disease) breathe better and reduce symptoms. You inhale the medication, and researchers will measure how well your lungs work and how you feel over time.
This study tests an inhaled medication called RB042 in healthy adults, healthy smokers, and people with COPD. It aims to see how the drug works in the body and whether it is safe, which could help in developing a new treatment for COPD.
This study tests whether a new inhaled medication called HSK39004 can help people with COPD breathe better and reduce shortness of breath. You'll receive either the medication or a placebo (inactive powder) and be monitored for safety and effectiveness.
This trial tests a new inhaled drug, HSK39004, to see if it safely improves breathing and quality of life in people with moderate to severe COPD. You may join if you are between 40 and 80, have a COPD diagnosis with certain lung function results, and have at least some shortness of breath with daily activities.
This study tests a new dry powder inhaler (HSK39004) for long-term safety in people with moderate to severe COPD. It may help if your breathing is limited despite current treatment.
Hear when a new COPD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.